Overview

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
CeNeRx BioPharma Inc.